Concord Medical Services (CCM) AI Stock Analysis

• Market Cap: $22.84M
• Dividend Yield: N/A
• Average Volume (3M): 25.64K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.05
• Revenue Growth: -22.38%
• EPS Growth: 56.66%
• Country: US
• Employees: 595
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -9.83
• Shares Outstanding: 2,815,458
• 10 Day Avg. Volume: 72,657
• 30 Day Avg. Volume: 25,639
• PEG Ratio: >-0.01
• Price to Book (P/B): >-0.01
• Price to Sales (P/S): 0.01
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: 47.46
• Enterprise Value/Revenue: 2.96
• Enterprise Value/Gross Profit: -25.90
• Enterprise Value/Ebitda: -3.02
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $5.50 ▲(11.56% Upside)

Concord Medical Services faces significant financial challenges, with negative profitability and cash flow issues being the most critical factors. Technical indicators suggest mixed momentum, but the overall outlook remains negative due to poor financial health and valuation metrics.

Concord Medical Services Business Overview & Revenue Model

Company Description

Concord Medical Services (CCM) is a leading provider of advanced radiotherapy services in China, specializing in precision cancer treatment through its network of radiotherapy centers. The company operates in the healthcare sector, focusing on oncology services, and offers a range of core products including radiotherapy treatment solutions, medical equipment leasing, and technical services to enhance patient care and treatment outcomes. CCM is dedicated to improving access to high-quality cancer treatment across the country through its state-of-the-art facilities and partnerships with major medical technology providers.

How the Company Makes Money

Concord Medical Services generates revenue primarily through the provision of radiotherapy services to cancer patients. The company earns income from patient treatment fees, which include charges for the use of advanced medical equipment and facilities. Additionally, CCM has established several key partnerships with medical device manufacturers, allowing it to lease cutting-edge technology and equipment to its centers, further contributing to its revenue stream. The leasing agreements and technical service contracts also provide a consistent source of income, while collaborations with government healthcare programs and hospitals enhance the company’s market presence and patient referral base.

Concord Medical Services Financial Statement Overview

Summary

Concord Medical Services is experiencing severe financial distress, with declining revenues, negative profit margins, and a heavily leveraged balance sheet. Persistent negative cash flows further emphasize the need for strategic restructuring.

Income Statement

Concord Medical Services has experienced a persistent decline in revenue with a sharp drop from $537M in 2023 to $384M in 2024. Negative gross profit and EBIT margins indicate significant operational challenges. The net profit margin remains deeply negative, reflecting ongoing financial struggles.

Balance Sheet

The company's balance sheet shows considerable financial distress, with negative stockholders' equity reflecting a heavily leveraged position. The debt-to-equity ratio is not calculable due to negative equity, signaling high risk. Total liabilities exceed assets, indicating solvency issues.

Cash Flow

Cash flows are under pressure, with consistently negative operating and free cash flows. Despite a growth in financing cash flow, the reliance on external financing is unsustainable given the weak free cash flow to net income ratio, which remains negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	365.76M	383.96M	537.40M	472.08M	485.63M	223.01M
Gross Profit	-41.85M	-79.16M	-76.61M	-152.41M	-56.90M	13.08M
EBITDA	-358.51M	-345.62M	-344.16M	-401.86M	-363.86M	-236.72M
Net Income	-163.12M	-308.24M	-297.66M	-489.66M	-271.43M	-309.99M
Balance Sheet
Total Assets	6.73B	6.73B	6.05B	6.00B	6.23B	5.33B
Cash, Cash Equivalents and Short-Term Investments	177.39M	350.85M	58.14M	158.28M	157.39M	334.26M
Total Debt	3.82B	3.93B	3.30B	3.24B	2.73B	2.35B
Total Liabilities	5.01B	5.11B	4.31B	3.99B	3.49B	2.93B
Stockholders Equity	-2.24B	-2.28B	-2.12B	-1.86B	-1.37B	-662.96M
Cash Flow
Free Cash Flow	0.00	-808.58M	-392.17M	-600.47M	-1.12B	-734.47M
Operating Cash Flow	0.00	-397.75M	-276.47M	-216.69M	-359.31M	-229.77M
Investing Cash Flow	0.00	-593.44M	-47.68M	-118.79M	-565.98M	-533.88M
Financing Cash Flow	0.00	1.15B	257.65M	383.09M	642.45M	1.14B

Concord Medical Services Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.93
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCM, the sentiment is Negative. The current price of 4.93 is below the 20-day moving average (MA) of 5.52, below the 50-day MA of 5.66, and below the 200-day MA of 5.56, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 41.23 is Neutral, neither overbought nor oversold. The STOCH value of 47.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CCM.

Concord Medical Services Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DCGO	50 Neutral	$105.63M	―	-5.98%	―	-41.31%	-163.08%
AMS	49 Neutral	$13.69M	-5.69	-9.49%	―	26.61%	-156.30%
JYNT	49 Neutral	$127.20M	―	-1.37%	―	-54.93%	―
CCM	44 Neutral	$22.84M	-1.01	―	―	-22.38%	56.66%
CCEL	44 Neutral	$34.94M	-73.26	―	9.30%	-0.29%	94.56%
PIII	40 Underperform	$60.81M	-0.17	-138.17%	―	4.20%	-54.16%

Concord Medical Services Corporate Events

Concord Medical Services Announces Director Resignation

On September 28, 2025, Mr. Yue Yu resigned as a Director of Concord Medical Services Holdings Limited, effective September 29, 2025, citing personal reasons. His resignation was not due to any disagreements with the company’s operations or policies, ensuring a smooth transition without impacting the company’s strategic direction.

Concord Medical Reports Improved Financials Amid Proton Therapy Expansion

Concord Medical Services announced its unaudited financial results for the first half of 2025, revealing a total net revenue of RMB200.6 million, an 8.3% decrease from the previous year. Despite a net loss of RMB27.1 million, the company showed significant improvement in its gross loss margin, which decreased from 19.0% to 2.1%, largely due to the commencement of proton therapy operations at Guangzhou Concord Cancer Hospital. This advancement has contributed to increased revenues in the hospital business, while the network business faced challenges due to decreased demand for medical equipment and software. The company remains committed to advancing proton therapy and enhancing operational efficiency, which is expected to improve patient outcomes and expand access to advanced diagnostic and therapeutic technologies.

Concord Healthcare Releases Interim Results for H1 2025

Concord Healthcare, a subsidiary of Concord Medical Services Holdings Limited, announced its interim results for the first half of 2025 on August 28, 2025. The announcement follows the listing of Concord Healthcare’s H shares on the Hong Kong Stock Exchange in January 2024, indicating a strategic move to enhance its market presence and financial transparency.

Concord Healthcare Completes Share Placement Under General Mandate

On July 29, 2025, Concord Healthcare Group Co., Ltd., a subsidiary of Concord Medical Services, successfully completed the placement of 48,723,600 new shares under a general mandate. The shares were placed at a price of HK$5.54 each to no fewer than six placees, marking a significant step in the company’s financial strategy and potentially strengthening its market position.

Concord Healthcare Announces New Share Placement

On July 22, 2025, Concord Healthcare, a subsidiary of Concord Medical Services Holdings Limited, announced a placing agreement with Guotai Junan Securities (Hong Kong) Limited. This agreement involves the placement of 48,723,600 new shares at a price of HK$5.54 per share, aimed at independent third-party investors. This move is part of Concord Healthcare’s strategic efforts to strengthen its financial position following its listing on the Hong Kong Stock Exchange in January 2024.